NF1 and glioma: AAV-K55 markedly enhanced tumor selectivity, reduced liver uptake, and demonstrated significant therapeutic efficacy in delivering the GRD-C24 transgene across multiple NF1 tumor models, including pNFs, MPNSTs, and gliomas [79].